Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K5LQ
|
||||
| Former ID |
DAP001064
|
||||
| Drug Name |
Pemirolast
|
||||
| Synonyms |
Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Allergic conjunctivitis [ICD9: 204.0, 372.0, 372.14, 995.3; ICD10:C91.0, H10, H10.45, T78.4] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Antiallergic Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H8N6O
|
||||
| InChI |
InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15)
|
||||
| InChIKey |
HIANJWSAHKJQTH-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 100299-08-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
8185373, 14773738, 14822841, 43115342, 46509034, 50065081, 50563413, 57313910, 85209679, 93166875, 96024435, 104313292, 123092154, 128063839, 131269071, 134338322, 135035415, 137007584, 137035161, 142971147, 160964226, 162178777, 164814579, 175268367, 178103901, 179150951, 179326618, 223797099, 226416213, 252355732
|
||||
| Target and Pathway | |||||
| Target(s) | Histamine H1 receptor | Target Info | Antagonist | [4] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
| Reactome | Histamine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| IL-4 Signaling Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7329). | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 4 | The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9. Epub 2008 May 8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.